Document Detail

Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization.
MedLine Citation:
PMID:  12103259     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The study assessed clinical outcomes of closure device use following percutaneous coronary revascularization using current standards of anticoagulation and antiplatelet therapy.
BACKGROUND: Evaluation of the outcomes of patients by use of vascular closure devices during coronary interventions employing current standards of anticoagulation and glycoprotein (GP) IIb/IIIa inhibitor therapy is limited.
METHODS: We evaluated outcomes of 4,525 consecutive patients who underwent percutaneous coronary intervention between July 1997 and April 2000. All patients received anticoagulation with heparin and GP IIb/IIIa inhibitor therapy with abciximab. The closure method was manual in 1,824 patients, Angioseal in 524 patients and Perclose in 2,177 patients. Procedural and hospital vascular outcomes were evaluated.
RESULTS: Closure device success was 97.1% Angioseal and 94.1% Perclose (p < 0.05). Minor vascular complications occurred in 1.8% of manual patients, 1.1% of Angioseal patients and 1.2% of Perclose patients (p = NS); major complications occurred in 1.3% of manual patients, 1.1% of Angioseal patients and 1.0% of Perclose patients (p = NS). Multivariate logistic regression identified only closure device failure as an independent predictor of a vascular complication. In patients with successful closure with a device, minor complications (0.8% vs. 1.8%, p < 0.05) and any complication (1.5% vs. 2.5%, p < 0.05) were reduced compared to manual compression.
CONCLUSIONS: Arterial closure following coronary interventions using anticoagulation and GP IIb/IIIa inhibitor therapy can be safely and effectively performed, with vascular complication rates similar to or lower than with manual pressure. Additionally, vascular complication rates using GP IIb/IIIa inhibitor therapy regardless of the method of arterial closure are equivalent to or lower than previously published rates of vascular complications.
Robert J Applegate; Mark A Grabarczyk; William C Little; Timothy Craven; Michael Walkup; Frederic R Kahl; Gregory A Braden; Kevin M Rankin; Michael A Kutcher
Related Documents :
11900289 - Analysis of troponin i levels after spontaneous implantable cardioverter defibrillator ...
2902779 - The efficacy of the addition of nifedipine in patients with mixed angina compared to pa...
19811939 - Comparative study of complete versus incomplete kawasaki disease in 59 pediatric patients.
10719829 - Advanced mitral annular calcification is associated with severe coronary calcification ...
16266039 - Prediction of coronary artery disease in patients undergoing carotid endarterectomy.
22335599 - Cxcl13 as a novel marker for diagnosis and disease monitoring in pediatric ptld.
16556669 - Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive ...
15758349 - The pathogenetic influence of i-parathyroid hormone on slipped capital femoral epiphysi...
7705119 - Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolatio...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  40     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-07-09     Completed Date:  2002-07-26     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  78-83     Citation Subset:  AIM; IM    
Section of Cardiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1045, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Anticoagulants / therapeutic use*
Hemostatic Techniques / instrumentation*
Heparin / therapeutic use*
Immunoglobulin Fab Fragments / therapeutic use*
Logistic Models
Middle Aged
Myocardial Revascularization*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Anticoagulants; 0/Immunoglobulin Fab Fragments; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 9005-49-6/Heparin; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infa...
Next Document:  Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and l...